Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
the efficacy and safety of bortezomib / dexamethasone combination therapy in patients with
relapsed or refractory T-cell lymphoma who have failed one or more treatments.
- primary purpose
1. Overall response rate
- secondary purpose
1. Progression-free survival and overall survival
2. Disease stabilization ratio
3. Duration of reaction
4. Safety Profile
5. Experiments on response prediction / immunological markers